CD274 and ovarian carcinoma: Additionally, conventional (MSI/MMR, PD-L1 expression, and TMB) and ovarian-cancer-specific (BRCA mutation and HRD) biomarkers have not effectively distinguished between patients who benefit most from ICIs.